Nasopharyngeal Carcinoma Clinical Trial
Official title:
the Garduate Institute of Microbiology in National Taiwan University
EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses. Unlike other human herpes viruses, EBV can only predominately infect two types of human cells: lymphoid cells and epithelial cells and its infection is associated with several human malignancies of these two cell types. The lymphoid cancers associated with EBV infection include Burkitt’s lymphoma, Hodgkin’s disease, B lymphoma in immunodeficient patients and T/NK cell lymphoma. The carcinomas associated with EBV are nasopharyngeal carcinoma and gastric carcinoma. One unique biological feature of EBV is that it can infect and immortalize primary B lymphocytes in vitro into lymphoblastoid cell lines (LCL). So far, limited information is known about the whole EBV infection process and its regulation mechanism for immortalization. In this project, three EBV infection models are setting up to reveal the cellular events and signal transduction pathway possibly involved in EBV infection process and immortalization course of action.
Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal
epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC
individuals are usually ten years younger than those of patients with other head and neck
cancers. Clinically, this early onset and high incidence of metastasis in NPC may contribute
to its poor prognosis. Fortunately, NPC is usually radio-and chemo-therapy sensitive during
the early stage. So, the more we understand NPC pathogenesis, the more efficient detection
methods would be developed for NPC early diagnosis and prognosis.
Four unique characteristics have been reported for NPC: geographic preference, heavy
infiltration of lymphocytes, high incidence of metastasis and association with Epstein-Barr
virus (EBV). According to our hypothesis that both cellular changes and viral factors are
crucial for NPC development, four major long-term study goals have been carried out in our
lab: (1) identification and characterization of the cellular and viral factors that are
involved in NPC formation, (2) elucidation of potencies of these molecules as clinical
diagnosis and prognosis markers of NPC, (3) investigation of the molecular and biological
linkage between EBV infection and NPC development and (4) establishment of a drug-screening
system for NPC chemotherapy.
Based on our assumption that both cellular genes and viral factors are involved in NPC
carcinogenesis, the following genes are chosen as the major study targets in this five-year
grant. Firstly, to asses the alteration of cellular gene expression, we choose three
cytokine genes 【interleukin (IL)-1, IL-7 and IL-13】, three inhibitors of apoptosis proteins
(IAP) genes (survivin, HIAP-1, and HIAP-2), two specific cellular genes (osteoblast-specific
factor-2 and polymeric immunoglobulin receptor) and one tumor suppressor gene (tumor
susceptibility gene TSG101) in our proposal. All these genes exhibit special expression
profiles in NPC biopsies in our preliminary study. So, the regulation and effect of these
genes in epithelial cells would be the study focus. Secondly, two EBV viral genes, Zta and
LMP2A, the former encoded immediately early lytic product and the later encoded latent
membrane protein, are selected for this study. In our previous grant, we found that Zta can
up-regulate TKT (trk-related tyrosine kinase) and matrix metalloproteinases (MMP)-1 which is
a down-stream effector of TKT. Therefore we will extend the study on how Zta and LMP2A
regulate and influence anti-apoptotic network and metastasis progression. Based on our
preliminary data, this proposal is highly approachable and the results may provide valuable
information for NPC diagnosis, prognosis and treatment.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
| Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
| Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
| Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
| Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
| Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
| Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |